Direct Inhibition of Mitochondrial Respiratory Chain Complex III by Cell ...

THE JOURNAL

OF

BIOLOGICAL CHEMISTRY

Vol. 272, No. 39, Issue of September 26, pp. 24154 –24158, 1997 Printed in U.S.A.

Direct Inhibition of Mitochondrial Respiratory Chain Complex III by Cell-permeable Ceramide* (Received for publication, July 7, 1997, and in revised form, August 5, 1997)

Tatyana I. Gudz‡§, Kou-Yi Tserng‡¶i, and Charles L. Hoppel‡i** From the Departments of ‡Medicine, **Pharmacology, and ¶Nutrition, Case Western Reserve University and iVeterans Affairs Medical Center, Cleveland, Ohio 44106

Ceramide is a lipid second messenger that mediates the effects of tumor necrosis factor a and other agents on cell growth and differentiation. Ceramide is believed to act via activation of protein phosphatase, prolinedirected protein kinase, or protein kinase C. Tumor necrosis factor a-induced common pathway of apoptosis is associated with an early impairment of mitochondria. Herein, we demonstrate that ceramide can directly inhibit mitochondrial respiratory chain function. In isolated mitochondria, a rapid decline of mitochondrial oxidative phosphorylation occurs in the presence of Nacetylsphingosine (C2-ceramide), a synthetic cell-permeable ceramide analog. An investigation of the site of ceramide action revealed that the activity of respiratory chain complex III is reduced by C2-ceramide with halfmaximum effect at 5–7 mM. In contrast, N-acetylsphinganine (C2-dihydroceramide), which lacks a functionally critical double bond and is ineffective in cells, did not alter mitochondrial respiration or complex III activity. We suggest that these in vitro observations may set the stage for identifying a novel mechanism of regulation of mitochondrial function in vivo.

The pro-inflammatory cytokine tumor necrosis factor-a (TNF-a)1 elicits a wide variety of cellular responses including profound alterations in transcriptional programs, perturbation of mitochondrial function, and apoptosis in a number of cell types (1, 2). Strong evidence supports a pivotal role for TNF-a in the genesis of septic shock (2), and it also has been implicated in ischemia reperfusion injury of heart (3). A recent report demonstrates that a physiologically relevant concentration of TNF-a induced apoptosis in rat cardiomyocytes as quantified by single cell microgel electrophoresis of nuclei and in situ 39 nick end labeling assay (4). Mitochondria are considered an early target in TNF-a-induced cytotoxicity because they appear swollen with a reduced number of cristae, in association with profound inhibition of mitochondrial respiration (1, 5, 6). A growing body of evidence suggests that treatment of cells * This work was supported in part by National Institutes of Health Grants AG12447 and DK36069 and by funds from the Medical Research Service of the Department of Veterans Affairs. The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked “advertisement” in accordance with 18 U.S.C. Section 1734 solely to indicate this fact. § To whom correspondence should be addressed: Medical Research Service, VA Medical Center, 10701 East Blvd., Cleveland, OH 44106. Tel.: 216-791-3800, Ext. 4630; Fax: 216-229-8509; E-mail: tig@po. cwru.edu. 1 The abbreviations used are: TNF-a, tumor necrosis factor-a; C2ceramide, N-acetylsphingosine; C2-dihydroceramide, N-acetylsphinganine; C6-ceramide, N-hexanoylsphingosine; PTP, permeability transition pore; MOPS, 3-(N-morpholino)-propanesulfonic acid; BSA, bovine serum albumin; CAPP, ceramide-activated protein phosphatase; SSM, subsarcolemmal mitochondria; IFM, interfibrillar mitochondria.

with TNF-a results in an electron transport inhibition at the level of complex III (1, 6) followed by an increased generation of oxygen radicals in mitochondria (7–9). However, the mechanism of TNF-a-induced inhibition of mitochondrial respiration has not been elucidated. The sphingomyelin pathway has been implicated as a major signaling mechanism mediating the action of a number of extracellular agents (such as TNF-a, Fas ligands, and chemotherapeutic agents) causing the activation of sphingomyelinases that cleave membrane sphingomyelin resulting in the formation of ceramide (10, 11). Synthetic cell-permeable ceramide analogs have been shown to mimic many TNF-a-induced cell responses (10 –13). In malignant and nonmalignant cell lines, ceramides specifically induce apoptosis that involves activation of interleukin-1b-converting enzyme-like proteases, whereas closely related dihydro-analogs are inactive (10). The intracellular targets for ceramide are poorly understood. Some of the cellular activities of ceramide appear to be mediated by ceramide-activated protein phosphatase (CAPP), proline-directed protein kinase, and protein kinase C (10, 14, 15). Given the multiplicity of TNF-a cellular effects that involve the activation of several signal transduction pathways, the impairment of mitochondrial respiration could have no causative links with the sphingomyelin signaling pathway. Alternatively, it could occur downstream of ceramide, for example, via the phosphorylation/dephosphorylation mechanism driven by CAPP. We propose that mitochondrial dysfunction results from the direct interaction of ceramide with mitochondrial respiratory chain. It is noteworthy that physiologically relevant and direct targets of ceramide are affected by ceramide in vitro, and only they could mediate the most proximal effects of ceramide in cells (10). To gain an insight into the mechanism of mitochondrial damage in TNF-a-treated cells, we tested the hypothesis that mitochondrial function is directly modulated by ceramide using isolated mitochondria. MATERIALS AND METHODS

Reagents—N-Acetylsphingosine (C2-ceramide), N-acetylsphinganine (C2-dihydroceramide), and N-hexanoylsphingosine (C6-ceramide) were obtained from Matreya. Decylubiquinone, cytochrome c, myelin basic protein, okadaic acid, and H7 were obtained from Sigma. Other chemicals were obtained from commercial sources and were reagent grade or better. Preparation of Mitochondria—Rat heart mitochondria were isolated as described previously (16), except that a modified Chappell-Perry buffer (Buffer A: 100 mM KCl, 50 mM MOPS, 1 mM EGTA, 5 mM MgSO4, 1 mM ATP, pH 7.4) was used for mitochondrial isolation. Briefly, cardiac tissue was finely minced, placed in buffer A supplemented with 0.2% bovine serum albumin (BSA), and homogenized with a Polytron tissue processor (Brinkman Instruments Inc.) for 2.5 s at a reostat setting of 6.0. The polytron homogenate was centrifuged at 500 3 g to separate the subsarcolemmal mitochondria (SSM) from myofibrils. The supernatant containing the SSM was saved, and the pellet was washed by resuspension in the buffer A supplemented with 0.2% BSA and recentrifuged at 500 3 g. The combined supernatants were centrifuged at 3000 3 g for 10 min to sediment SSM, washed twice, and then sus-

24154

This paper is available on line at http://www.jbc.org

Ceramide Inhibition of Complex III pended in a small volume of buffer B (100 mM KCl, 50 mM MOPS, 0.5 mM EGTA, pH 7.4). The myofibrillar pellet containing the interfibrillar mitochondria (IFM) was resuspended in buffer A, nagarse was added to a final concentration of 5 mg/g weight of tissue, and the suspension was immediately homogenized with Potter-Elvehjem homogenizer. Termination of the action of nagarse was accomplished by the addition of buffer A containing 0.2% BSA, followed by centrifugation at 5000 3 g. The pellet was resuspended in buffer A containing 0.2% BSA and centrifuged at 500 3 g to sediment myofibrillar debris. The pellet was washed, and the combined supernatants containing the IFM were centrifuged at 3000 3 g for 10 min to pellet IFM. IFM were washed twice and suspended in a small volume of buffer B. Protein concentration was assayed by Biuret method with BSA as the standard. Rat skeletal muscle mitochondria were isolated essentially as described (16) for interfibrillar subpopulation of heart mitochondria. Rat liver mitochondria were isolated as described (17). HL-60 cells were maintained in Dulbecco’s modified Eagle’s medium supplemented with a nutrient mixture of Ham’s F-12 (Sigma) containing 10% fetal calf serum plus an antibiotic/antimicotic mixture (Life Technologies, Inc.) and incubated at 37 °C with 5% CO2. Mitochondrial Respiration—Oxygen consumption by intact mitochondria was measured in a chamber equipped with a Clark type oxygen electrode (Yellow Springs Instrument Co.) at 30 °C. The incubations contained 0.5 mg/ml mitochondrial protein in 80 mM KCl, 50 mM MOPS, 5 mM KH2PO4, 1 mM EGTA, 0.1%, BSA, pH 7.4. After depletion of endogenous substrates by the addition of ADP, the substrate was added to the incubation. Then state 3 respiration was initiated by the addition of ADP or the uncoupled respiration rate was determined in the presence of the uncoupler, 2,4-dinitrophenol. Mitochondrial Oxidase Activities—Mitochondrial oxidase activities were determined with freeze-thawed mitochondria as described (18) and were performed at 30 °C using an oxygen electrode. Incubations contained 20 mM KH2PO4, 0.1 mM EDTA, 0.32 mM oxidized cytochrome c, mitochondrial protein, and substrates, which were added last. Activities were determined in the absence and in the presence of specific inhibitors. NADH oxidase activity was measured with 2.8 mM NADH and 7.5 mM rotenone as inhibitor. Durohydroquinol oxidase was measured with 2 mM durohydroquinol and 18 mM antimycin A as inhibitor. Cytochrome c oxidase was measured in the presence of 10 mM ascorbate and 1 mM N, N, N9, N9-tetramethyl-p-phenylenediamine, with and without 2 mM sodium azide as inhibitor. Complex III Activity—Complex III (decylubiquinol:ferricytochrome c oxidoreductase) activity was measured using a diode array spectrophotometer by following the increase in reduced cytochrome c absorbance as described (19). Mitochondria (1 mg/ml) were solubilized with 2% sodium cholate in 25 mM KH2PO4, pH 7.4, diluted 10-fold with 25 mM KH2PO4, pH 7.4, and this diluted solution was used for the measurement of complex III activity. The assay mixture contained 0.1% bovine serum albumin, 0.1 mM EDTA, 60 mM cytochrome c, 3 mM sodium azide, and 50 mM KH2PO4, pH 7.4. The mitochondrial sample (2 mg of mitochondrial protein or 0.07 mg of purified complex III or 80 mg of cellular protein) was added last into 1 ml of the assay mixture followed by the addition of ceramides where stated. After a 2-min equilibration period, the reaction was started by the addition of 100 mM decylubiquinol, and the increase in absorbance at 550 nm was monitored for 1 min. The initial rate was linear during the first 60 s. The activity was measured with and without 18 mM antimycin A in parallel cuvettes. The antimycin A-insensitive component, which represents nonenzymatic reduction of cytochrome c, was less than 20% of the total activity. The activity was calculated using an extinction coefficient of 19.1 mM21 cm21 for reduced cytochrome c and was expressed as the antimycin A-sensitive rate. The specific activity of the enzyme is expressed as micromoles of cytochrome c reduced/min per mg of enzyme protein. Decylubiquinol was synthesized according to Ref. 18 by reduction of decylubiquinone (10 mmol) with NaBH4 in 2 ml of a 1:1 ethanol:H2O mixture (v/v, pH 2). The decylubiquinol formed was extracted twice with 1 ml of diethylether: isooctane 2:1 (v/v). The combined organic phases were washed with 2 ml of 2 M NaCl and evaporated to dryness at room temperature under a steam of nitrogen. The residue was dissolved in ethanol, and the resulting light yellow solution was acidified by the addition of 10 ml of 0.1 M HCl. This solution was stable for at least 3 months when stored at 220 °C under light protection. RESULTS AND DISCUSSION

Treatment of isolated heart mitochondria oxidizing glutamate in the presence of ADP (state 3) with C2-ceramide resulted in immediate inhibition of ATP synthesis coupled respi-

24155

FIG. 1. C2-ceramide inhibition of the state 3 respiration rate in intact mitochondria. Respiration of rat heart interfibrillar mitochondria was measured as described under “Materials and Methods” with 10 mM glutamate as a substrate. Additions are indicated by arrows: Mito, 0.5 mitochondrial protein/ml; ADP, 2 mM; C2-ceramide, 10 mM. C2ceramide was dissolved in ethanol. Trace A, mitochondria respiring in the presence of the maximal amount of ethanol given in trace B. The numbers indicate the rates of oxygen consumption in nanoatoms of oxygen/min/mg of protein. The results shown are representative of four separate experiments.

ration (Fig. 1). Preincubation of mitochondria with C2-ceramide for 1–5 min did not increase the effect (data not shown). There was no change in the state 2 (only substrate for respiration is present) and state 4 (ADP-limiting) respiration rates in mitochondria treated with C2-ceramide at a concentration of 1–50 mM, compared with control (data not shown). Therefore, the permeability of the mitochondrial inner membrane was not affected by C2-ceramide under this condition. The sensitivity of mitochondrial oxidative phosphorylation (state 3 respiration) to ceramide inhibition varied depending upon the tissue. Liver mitochondria were most sensitive (IC50 5 20 mM), followed by subsarcolemmal and interfibrillar heart mitochondria (IC50 5 28 –31 mM). Mitochondria isolated from skeletal muscle were the least sensitive to ceramide with IC50 5 42 mM. In our experiments, glutamate was used as the substrate for mitochondrial respiration. Glutamate enters mitochondria via a specific transporter and is metabolized in the mitochondrial matrix by glutamate dehydrogenase generating NADH that in turn is oxidized by respiratory chain enzymes resulting in formation of ATP. The C2-ceramide-induced decrease in the state 3 respiration rate could be due to inhibition of substrate transporter, glutamate dehydrogenase activity, inhibition of respiratory chain enzyme activity(s), and/or inhibition of ATP synthesis machinery (ATP synthase, adenine nucleotide translocase, and phosphate transporter). To exclude the ATP synthesis machinery as a potential site of ceramide action, we treated mitochondria with C2-ceramide in the presence of uncoupler (2,4-dinitrophenol). The dose response of uncoupled mitochondria in the presence of C2-ceramide was almost identical to that seen with phosphorylating mitochondria (Fig. 2). These results suggest that the substrate transporter, glutamate dehydrogenase, or the respiratory chain enzymes could be the sites of C2-ceramide attack. To rule out the possibility that C2-ceramide affects substrate transporter and glutamate dehydrogenase, we used mitochondria that had been subjected to a freeze-thawing cycle that makes the mitochondria permeable to NADH. Thus, in permeabilized mitochondria, NADH can be used as a substrate and is readily oxidized by respiratory chain enzymes. NADH oxida-

24156

Ceramide Inhibition of Complex III

FIG. 2. Effect of C2-ceramide on respiration of phosphorylating and uncoupled mitochondria. Oxygen consumption was measured in intact rat heart interfibrillar mitochondria as described under “Materials and Methods” with 10 mM glutamate as a substrate. 1, mitochondria respiring in the presence of 2 mM ADP. 2, mitochondria uncoupled by 150 mM of DNP. The values are the means 6 S.D. from three separate mitochondrial preparations. Rates of oxygen consumption in control were 388 6 26 nAO/min/mg of protein.

tion requires the activity of complexes I, III, and IV. In the presence of C2-ceramide, a profound decrease in NADH oxidase activity occurred (Fig. 3), indicating that C2-ceramide indeed inhibits respiratory chain enzyme activity. Activities of other mitochondrial oxidases were further investigated to define the site of ceramide-induced inhibition of oxidative phosphorylation. C2-ceramide brought about a dose-dependent reduction in duroquinol oxidase (requires complex III and IV) but not in cytochrome c oxidase (requires complex IV; Fig. 3). Analysis of oxidase activity measurements reveals complex III as a primary site of C2-ceramide action. However, the coexisting block of complex I activity by C2-ceramide can be masked because of the complex III inhibition. To definitively examine C2-ceramide effect on the complex III, we measured maximally expressed activity of the complex III (decylubiquinol: ferricytochrome c oxidoreductase) in detergent treated mitochondria. C2-ceramide caused significant reduction of the complex III activity with an IC50 of 5 mM (Fig. 4). Increases in C2-ceramide concentrations resulted in increased inhibition of complex III activity up to 80% of control at 20 mM. Complex III has been shown to exert a low degree of control on electron flux through the mitochondrial respiratory chain (20), implying that marked changes of complex III activity must occur before significant decreases in maximal respiration rate are detected. Therefore, it was expected that the profound C2-ceramide-induced decline of complex III activity at a concentration of 5–10 mM remains undetected by respiration rate measurement in intact mitochondria (compare Figs. 2 and 4). Although C2-ceramide seems to interact with complex III directly in isolated mitochondria within 2 min of incubation, it is still possible that ceramide effect is mediated by phosphorylation/dephosphorylation events. Therefore, we determined the C2-ceramide-induced reduction of complex III activity in the presence of CAPP inhibitor, okadaic acid (50 nM) or prolinedirected protein kinase substrate, myelin basic protein (50 mM), or the protein kinase C inhibitor H7 (14 mM) (10, 14, 15). None of these compounds blocked the C2-ceramide inhibition of complex III activity in isolated mitochondria, indicating the lack of involvement of the intermediates in the effect of C2-ceramide. To further support the view that C2-ceramide directly interacts with mitochondrial complex III, we assessed the C2-ceramide effect on the activity of purified complex III, which has been

FIG. 3. Mitochondrial oxidase activities in the presence of C2ceramide. Frozen-thawed rat heart interfibrillar mitochondria were incubated as described under “Materials and Methods”. Activity was expressed as inhibitor-sensitive rate. Specific activities in control were as follows: NADH oxidase, 1690 nAO/min/mg protein; duroquinol (DHQ) oxidase, 2510 nAO/min/mg protein; cytochrome c oxidase, 4310 nAO/min/mg protein. The results are representative of three independent experiments.

FIG. 4. Inhibition of mitochondrial complex III activity by C2and C6-ceramide. Rat heart interfibrillar mitochondria were incubated as described under “Materials and Methods.” The activity was expressed as the antimycin A-sensitive rate. The values are the means 6 S.D. pooled from four mitochondrial preparations. Specific activities in control were 4640 6 480 millunits/mg protein.

isolated from the beef heart mitochondria and purified to homogeneity (Fig. 5). The activity of the purified complex III was decreased in concentration-dependent fashion up to 93% in the presence of 20 mM C2-ceramide (Fig. 5, curve 2) with halfmaximum effect at 7 mM. Next, it was important to establish specificity of ceramide inhibition of mitochondrial complex III. Low concentrations of C6-ceramide (1–5 mM), another synthetic cell-permeable ceramide analog, were as effective as C2-ceramide (Fig. 4). However, greater concentrations of C6-ceramide did not produce further reduction of complex III activity. The reason for such an interaction of C6-ceramide with the complex III is unclear and is currently under investigation in this laboratory. A close structural analog of C2-ceramide, C2-dihydroceramide, lacks the 4,5-trans-double bond in the sphingoid backbone, which has been shown to be critical for imparting the biological activity of ceramide (12). C2-dihydroceramide (5–20 mM) did not affect the complex III activity (Fig. 4 and Fig. 5, curve 1) nor oxidative phosphorylation (data not shown). Therefore, the ability of C2-ceramide to inhibit complex III activity is due to specific

Ceramide Inhibition of Complex III

FIG. 5. C2-ceramide inhibits the activity of purified complex III. Complex III isolated from beef heart mitochondria was incubated as described under “Materials and Methods.” The activity was expressed as the antimycin A-sensitive rate. 1, in the presence of C2-dihydroceramide; 2, in the presence of C2-ceramide. The values are the means 6 S.D. from three measurements. Similar results were obtained in two independent experiments.

structural requirements as opposed to nonspecific hydrophobic interactions. Evidence has recently been provided that ceramide contents in mitochondria isolated from the cells exposed to TNF-a are greatly elevated (21). The mechanism underlying the accumulation of ceramide in mitochondria is unclear, although the data indicate that ceramide is not locally produced. Having demonstrated the direct inhibition of complex III activity by C2-ceramide in isolated mitochondria, we sought to determine if treatment of the cells with TNF-a or C2-ceramide inhibits mitochondrial complex III activity. The HL-60 cells were incubated in Dulbecco’s modified Eagle’s medium (without serum) with 15 mM C2-ceramide or 80 ng/ml of TNF-a at 37 °C for 3 h and then washed with phosphate-buffered saline and collected in 25 mM potassium phosphate buffer, pH 7.4, containing 2% sodium cholate. The activity of complex III was 35 and 45% lower in the cells treated with C2-ceramide and TNF-a, respectively, compared with control. Taken together these data suggest that the inflammatory cytokines such as TNF-a leads to increased generation of ceramide followed by ceramide trafficking to mitochondria where ceramide interacts directly with complex III. This study further supports the notion that ceramide is a new modulator of respiratory chain function in mitochondria. An appreciation of the mechanisms by which mitochondria are integrated in cellular metabolism has evolved considerably in several decades of intensive investigation. But, the signal transduction pathways regulating mitochondrial function are just being explored. It has been established that Ca21 and cAMP are the second messengers that control mitochondrial enzyme activities such as matrix dehydrogenases and oxidative phosphorylation (22, 23). Our data indicate that sphingomyelindependent signal transduction pathway may participate in regulation of vital mitochondrial function. The data presented here suggest that mitochondrial respiratory complex III is a novel direct target of ceramide in cells. Our findings demonstrating the inhibition of complex III by ceramide in mitochondria have extended previous observations that mitochondrial respiration is impaired in the cells treated with TNF-a (1, 5, 6) and have also defined the mechanism of TNF-a effect on mitochondria. A rapid response of isolated mitochondria and purified complex III to ceramide treatment seems to exclude the involvement of intermediates. The concentrations

24157

of C2-ceramide that were required for complex III inhibition are similar to those employed in studies of the effects of ceramide in vivo (Refs. 13, 24, and 25; reviewed in Ref. 10). The profound inhibition of complex III activity by C2-ceramide but not by C2-dihydroceramide, which also is inactive in cells, implicates complex III as a potential mediator of proximal ceramide effects in cells. Whereas the specific mechanism whereby mitochondrial complex III can transduce the effects of ceramide is not known, there is a possibility that generation of free radical plays a role. Mammalian complex III is an 11-subunit protein complex that links proton translocation to electron transfer from ubiquinol to cytochrome c by the proton motive Q cycle mechanism (26, 27). Complex III has been established as an important source of oxygen radical production in the mitochondrial respiratory chain, the radicals being formed at the level of ubiquinone (28). Inhibitors of cytochrome b reoxidation via center i in the Qcycle (antimycin A, for example) potentiate autooxidation of unstable ubisemiquinone resulting in an increased oxygen radical generation (29). Whether ceramide affects cytochrome b reoxidation in the Q-cycle with subsequent generation of oxygen radicals certainly requires further investigation. This is in line with the recent study by Garcia-Ruiz et al. (21) where C2-ceramide treatment of isolated mitochondria led to the generation of hydrogen peroxide, which was dependent on the electron transport in the respiratory chain. In TNF-a- and C2-ceramide-treated cells, increased mitochondrial oxygen radical formation was also detected (7, 9, 21). Additionally, a recent report has described the opening of mitochondrial permeability transition pore (PTP) as an essential feature of the TNF-a cytotoxicity in L929 fibroblasts. Ceramide was able to replace TNF-a both in inducing PTP and in killing the cells (30). Thus, these data support the role of ceramide in the mitochondrial effects of TNF-a. In isolated mitochondria, the opening of PTP results in dissipation of an inner mitochondrial membrane potential, uncoupling of oxidative phosphorylation (increase in respiration state 4 rate), loss of low molecular solutes from mitochondrial matrix, and swelling of mitochondria (31). In our experiments, the uncoupling of oxidative phosphorylation that is suggestive of PTP opening was not detected, whereas complex III activity was reduced following ceramide treatment of mitochondria. This observation raises the possibility that mitochondrial PTP opening is proximal to ceramide binding to complex III. It is noteworthy that this pore can develop in isolated mitochondria and cells under the oxidative stress condition associated with increased free radical generation (32). Also, antioxidants can prevent the PTP opening (33). Certainly, it remains to be determined whether ceramide binding to complex III causes excessive free radical generation that favors the subsequent PTP opening or ceramide interacts with multiple sites in mitochondria via different mechanisms. A clearer understanding of the mechanisms responsible for modulation of mitochondrial function by ceramide may prove critical to the study of signal transduction pathways involved in growth suppression and apoptosis. Acknowledgments—We thank Dr. J. Kerner for rat skeletal muscle mitochondria, Dr. Shiow-Jen Jin for rat liver mitochondria, and Dr. N. Robinson for the generous gift of purified complex III. We thank Dr. L. Obeid for the helpful advice and Dr. S. Novgorodov and Dr. E. Lesnefsky for fruitful discussions and support. We are very grateful to Dr. A. Scarpa and Dr. F. Heinzel for critical reading of the manuscript and valuable comments. We thank Ronda Griffin for expert technical assistance with the cell culture. REFERENCES 1. Schulze-Ostroff, K., Bakker, A. C., Vanhaesebroeck, B., Beyaert, R., Jacob, W. A., and Fiers, W. (1992) J. Biol. Chem. 267, 5317–5323 2. Vassalli, P. (1992) Annu. Rev. Immunol. 10, 411– 452 3. Gurevitch, J., Frolkis, I., Yuhas, Y., Paz, Y., Matsa, M., Mohr, R., and

24158

Ceramide Inhibition of Complex III

Yakurevich, V. (1996) J. Am. Coll. Cardiol. 28, 247–252 4. Krown, K. A., Page, M. T., Nguyen, C., Zechner, D., Gutierrez, V., Comstock, K. L., Glembotski, C. C., Quintana, P. J. E., and Sabbadini, R. A. (1996) J. Clin. Invest. 98, 2854 –2865 5. Lancaster, J. R., Jr., Laster, S. M., and Gooding, L. R. (1989) FEBS Lett. 248, 169 –174 6. Jia, L., Kelsey, S. M., Grahn, M. F., Jiang, X.-R., and Newland, A. C. (1996) Blood 87, 2401–2410 7. Hennet, T., Richter, C., and Peterans, E. (1993) Biochem. J. 289, 587–592 8. Schulze-Ostroff, K., Beyaert, R., Vandevoorde, V., Haegeman, G., and Fiers, W. (1993) EMBO J. 12, 3095–3104 9. Goossens, V., Grooten, J., De Vos, K., and Fiers, W. (1995) Proc. Natl. Acad. Sci. U. S. A. 92, 8115– 8119 10. Hannun, Y. A. (1996) Science 274, 1855–1859 11. Kolesnick, R., and Golde, D. W. (1994) Cell 77, 325–328 12. Bielawska, A., Crane, H. M., Liotta, D., Obeid, L. M., and Hannun, Y. A. (1993) J. Biol. Chem. 268, 26226 –26232 13. Obeid, L. M., Linardic, C. M., Karolak, L. A., and Hannun Y. A. (1993) Science 259, 1769 –1771 14. Lui, J., Mathias, S., Yang, Z., and Kolesnick, R. N. (1994) J. Biol. Chem. 269, 3047–3052 15. Dobrowsky, R. T., Kamibayashi, C., Mumby, M. C., and Hannun, Y. A. (1993) J. Biol. Chem. 268, 15523–15530 16. Palmer, J. W., Tandler, B., and Hoppel, C. L. (1977) J. Biol. Chem. 252, 8731– 8739 17. Hoppel, C. L., DiMarco, J. P., and Tandler, B. (1979) J. Biol. Chem. 254, 4164 – 4170 18. Krahenbuhl, S., Chang, M., Brass, M., and Hoppel, C. L. (1991) J. Biol. Chem.

266, 20998 –21003 19. Krahenbuhl, S., Talos, C., Wiesmann, U., and Hoppel, C. L. (1994) Clin. Chim. Acta 230, 177–187 20. Taylor, R. W., Birch-Machin, M. A., Lowerson, S. A., and Turnbull, D. M. (1994) J. Biol. Chem. 269, 3523–3528 21. Garcia-Ruiz, C., Colell, A., Mari, M., Morales, A., and Fernandez-Checa, J. (1997) J. Biol. Chem. 272, 11369 –11377 22. McCormack, J. G., Halestrap, A., and Denton, R. M. (1990) Physiol. Rev. 70, 391– 425 23. Romani, A., Dowell, E, and Scarpa, A. (1991) J. Biol. Chem. 266, 24376 –24384 24. Okazaki, T., Bielawska, A., Bell, R. M., and Hannun, Y. A. (1990) J. Biol. Chem. 265, 15823–15831 25. Raines M. A., Kolesnick, R. N., and Golde, D. W. (1993) J. Biol. Chem. 268, 14572–14575 26. Mitchell, P. (1975) FEBS Lett. 56, 1– 6 27. Trumpower, B. L. (1990) J. Biol. Chem. 265, 11409 –11412 28. Cadenas, E., and Boveris, A. (1980) Biochem. J. 188, 31–37 29. Turrens, J. F., Alexandre, A., and Lehninger A. L. (1985) Arch. Biochem. Biophys. 237, 408 – 411 30. Pastorino, J. G., Simbula, G., Yamamoto, K., Glascott, P. A., Jr., Rothman, R. J., and Farber, J. L. (1996) J. Biol. Chem. 271, 29792–29798 31. Gunter, T. E., Gunter K. K., Sheu, S.-S., and Gavin, C. E. (1990) Am. J. Physiol. 267, C313–C339 32. Duchen, M. R., McGuinness, O., Brown, L. A., and Crompton, M. (1993) Cardiovasc. Res. 27, 1790 –1794 33. Gudz, T., Eriksson, O., Kushnareva Y., Saris, N.-E., and Novgorodov, S. (1997) Arch. Biochem. Biophys. 342, 143–156